Table 1 Baseline characteristics of included HNC patients
Overall N | Discovery N = 957 | Replication N = 322 | Total N = 1279 |
|---|---|---|---|
Period of treatment | 2007–2018 | 2018–2020 | 2007–2020 |
Gender; Female (%) | 313 (32.71) | 98(30.40) | 411(32.10) |
Mean age (SD) | 63.50 (11.75) | 65.70(11.63) | 63.90 (11.75) |
Age group (%) | Â | Â | Â |
 ≥ 55 | 209 (21.84) | 58(18.00) | 267(20.90) |
 56–69 | 455 (47.54) | 131(40.70)* | 586(45.80) |
 70 ≥ | 293 (30.62) | 133(41.30)*** | 426(33.30) |
Tumor site (%) | Â | Â | Â |
 Oral cavity | 180 (18.95) | 47(14.70) | 227(17.70) |
 Oropharynx | 194 (20.42) | 80(25.10) | 274(21.40) |
 Larynx | 256 (26.95) | 82(25.70) | 338(26.40) |
 Others | 320 (33.68) | 110(34.50) | 430(33.60) |
T-stage; T3, 4 (%) | 362 (37.83) | 155(51.70) | 517(40.42) |
N-stage; N1–3 (%) | 456 (47.65) | 154(51.70) | 610(47.49) |
Chemotherapy (%) | Â | Â | Â |
 No chemotherapy | 691 (73.98) | 222(71.20) | 913(71.4) |
 Concomitant chemo | 227 (24.30) | 79(25.30) | 306(23.90) |
 Radio + cetuximab | 16 ( 1.72) | 11(3.50) | 27(2.10) |
Radiotherapy | Â | Â | Â |
 Postoperative (%) | 409 (42.74) | 115(36.30) | 524(40.97) |
Volume Surrogate | Â | Â | Â |
 Glottic/laryngeal T1N0M0 | 123 (13.57) | 25(8.60)* | 148(11.60) |
 All other TxN0 sites | 329 (36.32) | 111(38.30) | 440(34.40) |
 TxN1-3 carcinomas | 454 (50.11) | 154(53.10) | 608(47.50) |